Viewing nowCombinationLaniglu Duo Extended-Release Tablet 2.5/1000mg (Linagliptin, Metformin Hydrochloride)
Metformin Hydrochloride 1000mg · Linagliptin Micronized 2.5mg
Tablet · Prescription medication · Combination
Allyco Pharmaceutical Co., Ltd.

MFDS item code 202400515 · Approved 2024.03.12 · Insurance code 656005530
Improvement of blood glucose control in patients with type 2 diabetes mellitus
This medication helps patients with type 2 diabetes effectively control their blood sugar levels in conjunction with dietary management and exercise therapy. It is used to reliably maintain blood sugar levels through the combination of linagliptin and metformin.
For antidiabetic therapy, the dose of this drug should be determined based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg and extended-release metformin hydrochloride 2000 mg. This drug should be taken once daily with a meal, preferably with the evening meal. To reduce gastrointestinal adverse effects associated with metformin use, the metformin hydrochloride dose should be increased gradually. Take 1 tablet of this drug 5/1000 mg extended-release tablet once daily. Patients taking this drug as a 2.5/1000 mg extended-release tablet should take 2 tablets together once daily. 1. Patients not currently treated with metformin: The initial total daily dose of this drug is linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving treatment with metformin - For patients whose blood glucose is not adequately controlled with metformin monotherapy, the initial dose of this drug is a total daily dose of linagliptin 5 mg and the patient's existing dose of metformin hydrochloride, according to the current treatment regimen. - For patients whose blood glucose is not adequately controlled with combination therapy of metformin and a sulfonylurea, or metformin and insulin, an initial dose of this drug consisting of a total daily dose of linagliptin 5mg and a dose of metformin hydrochloride similar to the patient's existing dose should be considered. When this drug is administered in combination with insulin or a sulfonylurea, a reduction in the insulin or sulfonylurea dose may be necessary to reduce the risk of hypoglycemia (see Precautions for Use, 2. Use with Caution in the Following Patients). - When switching from an immediate-release metformin formulation to an extended-release formulation, blood glucose control should be closely monitored and the dose adjusted appropriately if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this drug, the dose of this drug should correspond to the existing doses of linagliptin and extended-release metformin hydrochloride. Special populations Renal impairment As dose adjustment according to renal function is necessary, evaluation of renal function is recommended before treatment with this drug and periodically thereafter. No dose adjustment of this drug is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatine clearance (CrCl) of 45mL/min or more and less than 60mL/min, or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or more and less than 60mL/min/1.73m2, this drug may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this drug. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) to less than 45mL/min/1.73m2, this drug must be discontinued immediately.
This medication may rarely cause serious lactic acidosis or hypoglycemia, so caution is needed. Patients with allergies to any component of this medication or those with type 1 diabetes, severe renal impairment, liver dysfunction, acute infections, or heart diseases should not use this medication. If taken with insulin or sulfonylurea medications, dosage adjustments may be necessary due to increased risk of hypoglycemia. Patients with decreased renal function should undergo regular kidney function tests, and this medication should not be taken if kidney function is severely impaired. In cases of acute renal failure or receiving iodinated contrast agents, this medication should be temporarily discontinued and resumed only after kidney function has recovered. Pregnant or nursing women are advised to avoid using this medication and should consult a physician if planning a pregnancy. This medication should be swallowed whole and not chewed, crushed, or split; there is no need to worry if the coating of the tablet is expelled unchanged. Long-term use may lead to vitamin B12 deficiency; therefore, monitoring through blood tests may be necessary. Patients taking this medication should consult a doctor immediately if sudden abdominal pain, skin rashes, or blistering skin disease symptoms occur. Elderly patients are at higher risk of decreased kidney function, so dosage adjustments and regular kidney function tests are necessary. Overdosage may cause gastrointestinal disturbances or lactic acidosis, so the dosage must be strictly followed as per the doctor's instructions. Additionally, there may be interactions when taken with other medications, so patients should inform their doctors or pharmacists of any other medications they are taking.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to protect it from air and moisture, at a temperature between 1 and 30 degrees Celsius. Proper storage will maintain the medication's effectiveness and safety.
Oval-shaped extended-release tablet, white to almost white, with A251 engraved on one side.
28 tablets/box (7 tablets/PTP x 4), 30 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationMetformin Hydrochloride 1000mg · Linagliptin Micronized 2.5mg
Tablet · Prescription medication · Combination
Allyco Pharmaceutical Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
Linagliptin Micronized 2.5mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Samjin Pharmaceutical Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
CombinationLinagliptin Micronized 2.5mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Genewon Science Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.